The autumn colors are reaching near peak in Washington, D.C. and election fever is at its apex. By the next writing of a Weekly Roundup, we will know a lot more about the future direction of the country and of … Continue reading
One of the things I noted in my talk yesterday (see below) was that the Congressional races have far greater weight on the future of the regulation by the FDA of the pharmaceutical market. For those of you as intensely … Continue reading
Yesterday I gave a brief talk at the DTC Perspectives conference held in New Jersey called DTC in the Era of Consumer Choice. I thought I’d outline a few of my thoughts on the future of DTC here as well. … Continue reading
Morningstar health-care analysts offer their take on the candidates’ plans and their possible effects for health-care firms. Share this:
The third quarter saw some highly unusual activity on the part of FDA’s DDMAC in terms of both content and quantity. Addressing the latter first, the FDA issued 8 letters for the quarter, which is a substantial increase for the … Continue reading
